ACAD 250117 12.00P (ACAD250117P12000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

ACAD250117P12000

Watchlist

0.00
0.000.00%

15min DelayTrading Jan 10 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

ACADIA Pharmaceuticals (ACAD) Receives a Buy From RBC Capital
TipRanksJan 9 20:49 ET · Ratings
Mizuho Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Announces Target Price $20
Moomoo NewsJan 9 06:34 ET · Ratings
Analysts Conflicted on These Healthcare Names: Avadel Pharmaceuticals (AVDL) and ACADIA Pharmaceuticals (ACAD)
TipRanksJan 9 06:30 ET · Ratings
Further Weakness as ACADIA Pharmaceuticals (NASDAQ:ACAD) Drops 5.2% This Week, Taking Five-year Losses to 61%
Yahoo FinanceJan 8 14:58 ET
ACADIA Pharmaceuticals Analyst Ratings
BenzingaJan 3 10:58 ET · Ratings
Guggenheim Downgrades ACADIA Pharmaceuticals(ACAD.US) to Hold Rating, Announces Target Price $20
Moomoo NewsJan 3 06:31 ET · Ratings

Comments

Trytosaveabit

Dec 11, 2024 15:06

News

$ACADIA Pharmaceuticals (ACAD.US)$ Reuters· 1 min ago
ACADIA Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Jaguar8

Nov 26, 2024 23:04

My Wednesday Watchlist. Trade the chart. Do not be impulsive. 11 stocks on watchlist today ran.

$HWH International (HWH.US)$ 13D 88.9%. China stock. Low float. SI 214%✅
$Infobird Software (IFBD.US)$ Completed $40M acquisition. China stock. Low float. 0 shares LTB✅
$Ocean Power Technologies (OPTT.US)$ Form 4 insider buying. 0 shares LTB✅
$T Stamp (IDAI.US)$ Ran today. Up after hours. Possible catalyst. Low float. 0 shares LTB✅
$Syra Health (SYRA.US)$ Recent Form 4s multiple insider loading. Low fl...

Jaguar8

Nov 26, 2024 15:13

NEWS

$ACADIA Pharmaceuticals (ACAD.US)$
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
Acadia Pharmaceuticals (NASDAQ: ACAD) has secured an exclusive worldwide license agreement with Saniona for SAN711, a first-in-class GABAA-α3 positive allosteric modulator.
The company plans to develop SAN711 for essential tremor treatment, with Phase 2 studies expected to begin in 2026. Under the agreement, Saniona will receive a $28 million upfront payment plus potential ...

Trytosaveabit

Nov 26, 2024 15:08

News

$ACADIA Pharmaceuticals (ACAD.US)$ Reuters· 1 min ago
ACADIA Pharmaceuticals Inc - Saniona to Receive $28 Million Upfront Plus up to $582 Million in Milestones with exclusive licensing agreement with Saniona for San711

Trytosaveabit

Nov 5, 2024 15:06

News

$ACADIA Pharmaceuticals (ACAD.US)$ Reuters· just
ACADIA Pharmaceuticals Enters Into an Agreement to Sell Its Rare Pediatric Disease Priority Review Voucher for $150 Million